Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma

Inclusion Criteria: documented history of multiple myeloma, failed at least two prior regimens for multiple myeloma, 18 years of age or older, ECOG(Zubrod)PS of 0 to 2, screening evaluation for determining eligibility prior to enrollment, signed informed consent form, Exclusion Criteria: concomitant therapy medications including corticosteroids or other chemotherapy that is or may be active against myeloma , renal insufficiency (serum creatinine levels of > 2mg/dL), mucosal bleeding, any condition which in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study. clinically relevant active infection or co-morbid medical conditions. prior malignancy(within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient is has been disease-free for at least 3 years. patients with non-secretory myeloma. as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be excluded.